

Perioperative Gene Analysis Report

Evidence of Clinical Value (Bibliography)

7. Codeine [package insert]. Columbus, OH: Roxane Laboratories, Inc; 2013.
8. Coumadin® [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2011.
14. FDA Drug Safety Communication: Safety review update of codeine use in children; new Boxed Warning and Contraindication on use after tonsillectomy and/or adenoidectomy. 2013. Accessed 2/18/2014.
37. Barratt DT, Bandak B, Klepstad P, et al. Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study. *Pharmacogenet Genomics*. Apr 2014;24(4):185-194.
38. Berthele A, Platzer S, Jochim B, et al. COMT Val108/158Met genotype affects the mu-opioid receptor system in the human brain: evidence from ligand-binding, G-protein activation and preproenkephalin mRNA expression. *Neuroimage*. Oct 15 2005;28(1):185-193.
55. Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update. *Clin Pharmacol Ther*. Apr 2014;95(4):376-382.
57. de Leon J, Dinsmore L, Wedlund P. Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers. *Journal of clinical psychopharmacology*. Aug 2003;23(4):420-421.
60. Eckhardt K, Li S, Ammon S, Schanzle G, Mikus G, Eichelbaum M. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. *Pain*. May 1998;76(1-2):27-33.
83. Kaplan HL, Busto UE, Baylon GJ, et al. Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability. *J Pharmacol Exp Ther*. Apr 1997;281(1):103-108.
86. Kirchheiner J, Keulen JT, Bauer S, Roots I, Brockmoller J. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. *Journal of clinical psychopharmacology*. Feb 2008;28(1):78-83.
90. Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. *Lancet*. Aug 19 2006;368(9536):70.
91. Kowarik MC, Einhauser J, Jochim B, et al. Impact of the COMT Val(108/158)Met polymorphism on the mu-opioid receptor system in the human brain: mu-opioid receptor, met-enkephalin and beta-endorphin expression. *Neurosci Lett*. Jan 11 2012;506(2):214-219.
95. Landau R, Liu SK, Blouin JL, Carvalho B. The effect of OPRM1 and COMT genotypes on the analgesic response to intravenous fentanyl labor analgesia. *Anesth Analg*. Feb 2013;116(2):386-391.
103. Madadi P, Ross CJ, Hayden MR, et al. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. *Clin Pharmacol Ther*. Jan 2009;85(1):31-35.
110. Mura E, Govoni S, Racchi M, et al. Consequences of the 118A>G polymorphism in the OPRM1 gene: translation from bench to bedside? *J Pain Res*. 2013;6:331-353.
115. Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. *Clin Pharmacol Ther*. Nov 1993;54(5):463-472.
121. Poulsen L, Brosen K, Arendt-Nielsen L, Gram LF, Elbaek K, Sindrup SH. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. *European journal of clinical pharmacology*. 1996;51(3-4):289-295.
124. Ravvag TT, Klepstad P, Baar C, et al. The Val158Met polymorphism of the human catechol-Omethyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. *Pain*. Jul 2005;116(1-2):73-78.
125. Ravvag TT, Ross JR, Sato H, Skorpen F, Kaasa S, Klepstad P. Genetic variation in the catechol-Omethyltransferase (COMT) gene and morphine requirements in cancer patients with pain. *Molecular pain*. 2008;4:64.
130. Sadhasivam S, Chidambaran V. Pharmacogenomics of opioids and perioperative pain management. *Pharmacogenomics*. Nov 2012;13(15):1719-1740.
131. Samer CF, Daali Y, Wagner M, et al. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. *British journal of pharmacology*. Jun 2010;160(4):919-930.
139. Sia AT, Lim Y, Lim EC, et al. A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia. *Anesthesiology*. Sep 2008;109(3):520-526.
143. Stamer UM, Lehnen K, Hothker F, et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. *Pain*. Sep 2003;105(1-2):231-238.
144. Stamer UM, Musshoff F, Kobilay M, Madea B, Hoefl A, Stuber F. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. *Clin Pharmacol Ther*. Jul 2007;82(1):41-47.
145. Stamer UM, Stuber F, Muders T, Musshoff F. Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication. *Anesth Analg*. Sep 2008;107(3):926-929.
146. Stamer UM, Zhang L, Book M, Lehmann LE, Stuber F, Musshoff F. CYP2D6 genotype dependent oxycodone metabolism in postoperative patients. *PLoS One*. 2013;8(3):e60239.
147. Stamer UM, Zhang L, Stuber F. Personalized therapy in pain management: where do we stand? *Pharmacogenomics*. Jun 2010;11(6):843-864.
148. Stauble ME, Moore AW, Langman LJ, et al. Hydrocodone in postoperative personalized pain management: pro-drug or drug? *Clin Chim Acta*. Feb 15 2014;429:26-29.
153. Swen JJ, Nijenhuis M, de Boer A, et al. Pharmacogenetics: from bench to byte—an update of guidelines. *Clin Pharmacol Ther*. May 2011;89(5):662-673.

* DxSurgical is not intended to diagnose disease or illness. It is a genetic test that detects the presence of certain DNA variations that may impact response to medications used in the surgical setting or which potentially contribute to risk of certain surgical complications.

Perioperative Gene Analysis Report Evidence of Clinical Value (Bibliography) Continued

154. Tammimaki A, Mannisto PT. Catechol-O-methyltransferase gene polymorphism and chronic human pain: a systematic review and meta-analysis. *Pharmacogenet Genomics*. Sep 2012;22(9):673-691.
160. Vuilleumier PH, Stamer UM, Landau R. Pharmacogenomic considerations in opioid analgesia. *Pharmacogenomics and personalized medicine*. 2012;5:73-87.
162. Walter C, Lotsch J. Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment. *Pain*. Dec 2009;146(3):270-275.
163. Wang G, Zhang H, He F, Fang X. Effect of the CYP2D6*10 C188T polymorphism on postoperative tramadol analgesia in a Chinese population. *European journal of clinical pharmacology*. Nov 2006;62(11):927-931.
167. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. *Drug Metab Rev*. 2009;41(2):89-295.
169. Zubieta JK, Heitzeg MM, Smith YR, et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. *Science*. Feb 21 2003;299(5610):1240-1243.
171. Zwisler ST, Enggaard TP, Noehr-Jensen L, et al. The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism. *Basic & clinical pharmacology & toxicology*. Apr 2009;104(4):335-344.
172. Johnson JA, Gong L, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. *Clin Pharmacol Ther*. Oct 2011;90(4):625-629.
184. Candiotti KA, Yang Z, Buric D, et al. Catechol-o-methyltransferase polymorphisms predict opioid consumption in postoperative pain. *Anesth. Analg*. Nov 2014;119(5):1194-1200.
195. Hwang IC, Park JY, Myung SK, Ahn HY, Fukuda K, Liao Q. OPRM1 A118G Gene Variant and Postoperative Opioid Requirement: A Systematic Review and Meta-analysis. *Anesthesiology*. Oct 2014;121(4):825-834.
209. Baber M, Chaudhry S, Kelly L, et al. The pharmacogenetics of codeine pain relief in the postpartum period. *Pharmacogenomics J*. Mar 10 2015.
213. Lassen D, Damkier P, Brosen K. The pharmacogenetics of tramadol. *Clin. Pharmacokinet*. Apr 25 2015.
215. Orliaguet G, Hamza J, Couloigner V, et al. A case of respiratory depression in a child with ultrarapid CYP2D6 metabolism after tramadol. *Pediatrics*. Mar 2015;135(3):e753-755.
217. Takashina, Y., T. Naito, Y. Mino, T. Yagi, K. Ohnishi, and J. Kawakami. 2012. Impact of CYP3A5 and ABCB1 gene polymorphisms on fentanyl pharmacokinetics and clinical responses in cancer patients undergoing conversion to a transdermal system. *Drug Metab. Pharmacokinet*. 27:414-421.
218. Tanaka, N., T. Naito, T. Yagi, M. Doi, S. Sato, and J. Kawakami. 2014. Impact of CYP3A5*3 on plasma exposure and urinary excretion of fentanyl and norfentanyl in the early postsurgical period. *Ther. Drug Monit*. 36:345-352.
219. Anectine® [package insert]. Princeton, NJ: Sandoz Inc; 2010.
220. Maynard G. Preventing hospital-associated venous thromboembolism: a guide for effective quality improvement, 2nd ed. Rockville, MD: Agency for Healthcare Research and Quality; October 2015. AHRQ Publication No. 16-0001-EF.
221. Abohelaika S, Wynne H, Avery P, Kamali F. Influence of CYP2C9 polymorphism on the fall in International Normalized Ratio in patients interrupting warfarin therapy before elective surgery. *Journal of thrombosis and haemostasis: JTH*. 2015;13(8):1436-1440.
222. Abohelaika S, Wynne H, Cope L, Kamali F. The impact of genetics on the management of patients on warfarin awaiting surgery. *Age and ageing*. 2015;44(4):721-722.
223. Bartels CF, Jensen FS, Lockridge O, et al. DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites. *American journal of human genetics*. 1992;50(5):1086-1103.
224. Bretlau C, Sorensen MK, Vedersoe AL, Rasmussen LS, Gatke MR. Response to succinylcholine in patients carrying the K-variant of the butyrylcholinesterase gene. *Anesthesia and analgesia*. 2013;116(3):596-601.
225. Candiotti KA, Birnbach DJ, Lubarsky DA, et al. The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis? *Anesthesiology*. 2005;102(3):543-549.
226. de Jonge H, Elens L, de Loor H, van Schaik RH, Kuypers DR. The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients. *The pharmacogenomics journal*. 2015;15(2):144-152.
227. Ehrenforth S, Nemes L, Mannhalter C, et al. Impact of environmental and hereditary risk factors on the clinical manifestation of thrombophilia in homozygous carriers of factor V:G1691A. *Journal of thrombosis and haemostasis: JTH*. 2004;2(3):430-436.
228. Elens L, Nieuweboer A, Clarke SJ, et al. CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. *Pharmacogenomics*. 2013;14(2):137-149.
229. Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141 (2 Suppl):e227S-277S.
230. Grody WW, Griffin JH, Taylor AK, Korf BR, Heit JA, Group AFVLW. American College of Medical Genetics consensus statement on factor V Leiden mutation testing. *Genetics in medicine: official journal of the American College of Medical Genetics*. Mar-Apr 2001;3(2):139-148.
231. Kaiser R, Sezer O, Papias A, et al. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. 2002;20(12):2805-2811.
232. Levano S, Ginz H, Siegemund M, et al. Genotyping the butyrylcholinesterase in patients with prolonged neuromuscular block after succinylcholine. *Anesthesiology*. 2005;102(3):531-535.
233. Okubo M, Murayama N, Shimizu M, Shimada T, Guengerich FP, Yamazaki H. CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomes. *The Journal of toxicological sciences*. 2013;38(3):349-354.
234. Seng KY, Hee KH, Soon GH, et al. CYP3A5*3 and bilirubin predict midazolam population pharmacokinetics in Asian cancer patients. *Journal of clinical pharmacology*. 2014;54(2):215-224.

Perioperative Gene Analysis Report Evidence of Clinical Value (Bibliography) Continued

235. Soliday FK, Conley YP, Henker R. Pseudocholinesterase deficiency: a comprehensive review of genetic, acquired, and drug influences. *AANA journal*. 2010;78(4):313-320.
236. Wahlander K, Larson G, Lindahl TL, et al. Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery. *Thrombosis and haemostasis*. 2002;87(4):580-585.
237. Wong M, Balleine RL, Collins M, Liddle C, Clarke CL, Gurney H. CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. *Clinical pharmacology and therapeutics*. 2004;75(6):529-538.
238. Yen T, Nightingale BN, Burns JC, Sullivan DR, Stewart PM. Butyrylcholinesterase (BCHE) genotyping for post-succinylcholine apnea in an Australian population. *Clinical chemistry*. 2003;49(8):1297-1308.
239. American Society of Plastic Surgeons VTE Task Force: Risk Assessment and Prevention. 2011. Accessed 9/30/2016
240. Bell GC, Caudle KE, Whirl-Carrillo M, Gordon RJ, Hikino K, Prows CA, Gaedigk A, Agundez JAG, Sadhasivam S, Klein TE, Schwab M. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron. *Clinical pharmacology and therapeutics*. 2016; Accepted Author Manuscript. doi:10.1002/cpt.598.
241. Zuo P, Haberer LJ, Fang L, Hunt TL, Ridgway D, Russo MW. Integration of modeling and simulation to support changes to ondansetron dosing following a randomized, double-blind, placebo-, and active-controlled thorough QT study. *The Journal of Clinical Pharmacology*. 2014; 54:1221–1229.
242. Nachimuthu S, Assar MD, Schussler JM. Drug-induced QT interval prolongation: mechanisms and clinical management. *Therapeutic Advances in Drug Safety*. 2012;3(5):241-253.
243. Gan TJ, Diemunsch P, Habib AS, Kovac A, Kranke P, Meyer TA, Watcha M, Chung F, Angus S, Apfel CC, Bergese SD, Candiotti KA, Chan MT, Davis PJ, Hooper VD, Lagoo-Deenadayalan S, Myles P, Nezat G, Philip BK, Tramèr MR. Consensus guidelines for the management of postoperative nausea and vomiting. *Anesthesia and Analgesia*. 2014 Jan;118(1):85-113.



Contact CogenDx to learn more.

Client Services: 877.866.0603

www.cogendx.com

CogenDx is a brand of Millennium Health, LLC

The CogenDx logo is a service mark or registered service mark of Millennium Health, LLC or its subsidiaries in the United States and other Countries. All other trademarks used herein are the property of their respective owners. This clinical laboratory developed test (LDT) was developed and its performance characteristics determined by Millennium Health, LLC and has not been cleared or approved by the US Food and Drug Administration (FDA). This LDT is a clinical test and its results should be used with other clinical observations and diagnostic findings for patient case management. Millennium Health, LLC maintains certification in accordance with Clinical Laboratory Improvement Amendments of 1988 and is accredited by the College of American Pathologists.

DXS-005-V01 PGA Version 5.2.0

© 2017 Millennium Health 04/2017